Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: Meta-analysis of randomized clinical trials

Lung Cancer

Volumn 63, Issue 1, 2009, Pages 50-57

  Bria, Emilio ^a   Gralla, Richard J ^b   Raftopoulos, Harry ^b   Cuppone, Federica ^a   Milella, Michele ^a   Sperduti, Isabella ^a   Carlini, Paolo ^a   Terzoli, Edmondo ^a   Cognetti, Francesco ^a   Giannarelli, Diana ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b North Shore Long Island Center for Advanced Medicine   (United States)

Author keywords

Adjuvant; Chemotherapy; Meta analysis; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 57649109776     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.05.002     Document Type: Article

References (50)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics. CA Cancer J Clin 58 (2008) 71-96
2. Spira A., and Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 350 (2004) 379-392
3. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257-263.
4. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2005:CD002142.
5. Burdett S., and Stewart L. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 47 (2005) 81-83
6. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
7. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
8. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
9. Imaizumi M. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer 49 (2005) 85-94
10. Keller S.M., Adak S., Wagner H., et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 343 (2000) 1217-1222
11. Mineo T.C., Ambrogi V., Corsaro V., et al. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur J Cardiothorac Surg 20 (2001) 378-384
12. Nakagawa K., Tada H., Akashi A., et al. Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer. Br J Cancer 95 (2006) 817-821
13. Roselli M., Mariotti S., Ferroni P., et al. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: long-term survival in a randomized study. Int J Cancer 119 (2006) 955-960
14. Scagliotti G.V., Fossati R., Torri V., et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 95 (2003) 1453-1461
15. Tada H., Tsuchiya R., Ichinose Y., et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 43 (2004) 167-173
16. Waller D., Peake M.D., Stephens R.J., et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26 (2004) 173-182
17. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
18. Xu G., Rong T., and Lin P. Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients. Chin Med J (Engl) 113 (2000) 617-620
19. Strauss G.M., Herndon II J.E., Maddaus M.A., et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633 [meeting abstracts]. J Clin Oncol 24 (2006) 7007
20. Levels of evidence for adult cancer treatment studies, health professional version (2004), National Cancer Institute
21. Pignon J.P., and Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol 2 (2001) 475-482
22. Pisters K.M., and Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol 23 (2005) 3270-3278
23. Bria E., Nistico C., Cuppone F., Carlini P., Ciccarese M., Milella M., et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 106 (2006) 2337-2344
24. Strauss GM, Herndon JE, II, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. 2006:7007.
25. Ardizzoni A., Boni L., Tiseo M., Fossella F., Shiller J.H., Paesmans M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99 (2007) 847-857
26. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., and Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 3852-3859
27. Zojwalla N.J., Raftopoulos H., and Gralla R.J. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients [meeting abstracts]. J Clin Oncol 22 (2004) 7068
28. Parmar M.K., Torri V., and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17 (1998) 2815-2834
29. Case L.D., Kimmick G., Paskett E.D., Lohman K., and Tucker R. Interpreting measures of treatment effect in cancer clinical trials. Oncologist 7 (2002) 181-187
30. Parmar M.K.B., and Machin D. Survival analysis: a practical approach (1995), John Wiley, Chichester (England)
31. Altman D.G. Confidence intervals for the number needed to treat. BMJ 317 (1998) 1309-1312
32. Pisters K.M., Evans W.K., Azzoli C.G., Kris M.G., Smith C.A., Desch C.E., et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 25 (2007) 5506-5518
33. Lagakos S.W. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 354 (2006) 1667-1669
34. Wang R., Lagakos S.W., Ware J.H., Hunter D.J., and Drazen J.M. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 357 (2007) 2189-2194
35. Bria E., Giannarelli D., and Terzoli E. Treatment of resected non-small-cell lung cancer. N Engl J Med 353 (2005) 1523-1524 [author reply: 1523-24]
36. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients [meeting abstracts]. J Clin Oncol (2008) (in press)
37. Barlesi F., and Pujol J.L. Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials. Lung Cancer 49 (2005) 289-298
38. Raftopoulos H., Gralla R.J., D'Auria G., Nelli F., and Bria E. Assessing the role of cisplatin dose and dose intensity (DI) in advanced non-small cell lung cancer (NSCLC): a comprehensive review of randomized trials 1992-2002. Proceedings of the American Society of Clinical Oncology Meeting (ASCO), Chicago, IL, US. J Clin Oncol (2003)
39. Raftopoulos H., Gralla R.J., Bria E., Eid E., and Stoopler M.B. Assessing the role of chemotherapy in advanced non-small cell lung cancer (NSCLC): a comprehensive review of large, randomized trials 1991-2001. Proceedings of the American Society of Clinical Oncology Meeting (ASCO), Orlando, FL, US. J Clin Oncol (2002)
40. Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., and Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292 (2004) 470-484
41. Berghmans T., Paesmans M., Meert A.P., Mascaux C., Lothaire P., Lafitte J.J., et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 49 (2005) 13-23
42. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., and Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22 (2004) 3860-3867
43. Sedrakyan A., Van Der Meulen J., O'Byrne K., Prendiville J., Hill J., and Treasure T. Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 128 (2004) 414-419
44. Piedbois P., and Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol 22 (2004) 3839-3841
45. Chao C., Studts J.L., Abell T., Prendiville J., Hill J., Treasure T., et al. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making. J Clin Oncol 21 (2003) 4299-4305
46. Soares H.P., Kumar A., and Djulbegovic B. Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev 33 (2007) 87-89
47. Simes R.J. Confronting publication bias: a cohort design for meta-analysis. Stat Med 6 (1987) 11-29
48. Burdett S., Stewart L.A., Tierney J.F., Le Pechoux C., on behalf of the, and NSCLC Collaborative Group. Supportive care and chemotherapy (CT) versus supportive care alone in advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs) [meeting abstracts]. J Clin Oncol 25 (2007) 7582
49. Le Pechoux C., Tribodet H., Pignon J.P., Burdett S., and on behalf of the NSCLC Collaborative Group. Surgery (S) and radiotherapy (RT) plus adjuvant chemotherapy (CT) versus surgery and radiotherapy in non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs) [meeting abstracts]. J Clin Oncol 25 (2007) 7521
50. Stewart L.A., Burdett S., Tierney J.F., Pignon J., and on behalf of the NSCLC Collaborative Group. Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT) [meeting abstracts]. J Clin Oncol 25 (2007) 7552